Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2026)
Nurix Therapeutics (NRIX) reported Change in Account Payables of -$461000.0 for Q1 2026, up 85.63% year-over-year from -$248337.9 in Q1 2025, and down 115.24% quarter-over-quarter from $3.0 million in Q4 2025.
Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of Change in Account Payables data on file, last reported at -$461000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$461000.0, up 85.63% year-over-year; the trailing twelve-month figure through Feb 2026 was $2.1 million (down 27.71% YoY), and the FY2025 annual result was -$630000.0, down 112.09% from the prior year.
- Change in Account Payables declined to -$461000.0 in Q1 2026 per NRIX's latest filing, from $3.0 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $7.6 million in Q4 2024 and troughed at -$3.2 million in Q1 2025.
- A 5-year average of $342176.5 and a median of -$461000.0 in 2026 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables surged 617.24% in 2023, then plunged 332.5% in 2024.
- A 5-year view of Change in Account Payables shows it stood at -$899000.0 in 2022, then surged by 617.24% to $4.6 million in 2023, then jumped by 63.12% to $7.6 million in 2024, then slumped by 60.12% to $3.0 million in 2025, then sank by 115.24% to -$461000.0 in 2026.
- Business Quant data shows NRIX's Change in Account Payables at -$461000.0 in Q1 2026, $3.0 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -461,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -461,000.00 |
| Feb 28, 2026 | -461,000.00 |
| Nov 30, 2025 | 3.03 Mn |
| Nov 30, 2025 | 3.03 Mn |
| Aug 31, 2025 | 2.23 Mn |
| Aug 31, 2025 | 2.23 Mn |
| May 31, 2025 | -2.68 Mn |
| May 31, 2025 | -2.68 Mn |
| Feb 28, 2025 | -3.21 Mn |
| Feb 28, 2025 | -3.21 Mn |
| Nov 30, 2024 | 7.59 Mn |
| Nov 30, 2024 | 7.59 Mn |
| Aug 31, 2024 | 1.10 Mn |
| Aug 31, 2024 | 1.10 Mn |
| May 31, 2024 | -2.54 Mn |
| May 31, 2024 | -2.54 Mn |
| Feb 29, 2024 | -930,000.00 |
| Feb 29, 2024 | -930,000.00 |
| Nov 30, 2023 | 4.65 Mn |
| Nov 30, 2023 | 4.65 Mn |